MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy

Zhang,Jilei; Shi,Jinlong; Zhang,Gaoqi; Zhang,Xinpei; Yang,Xinrui; Yang,Siyuan; Wang,Jing; Hu,Kai; Ke,Xiaoyan; Fu,Lin

doi:10.3892/ol.2019.10217

MicroRNA‑425 upregulation indicates better prognosis in younger acute myeloid leukemia patients undergoing chemotherapy

Authors:
- Jilei Zhang
- Jinlong Shi
- Gaoqi Zhang
- Xinpei Zhang
- Xinrui Yang
- Siyuan Yang
- Jing Wang
- Kai Hu
- Xiaoyan Ke
- Lin Fu
View Affiliations

Affiliations: Department of Hematology and Lymphoma Research Center, Peking University, Third Hospital, Beijing 100191, P.R. China, Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: April 4, 2019 https://doi.org/10.3892/ol.2019.10217
Pages: 5793-5802

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate whether the expression levels of microRNA‑425 (miR‑425) were associated with the prognosis of acute myeloid leukemia (AML) in patients treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo‑HSCT). A total of 162 AML patients were enrolled and divided into chemotherapy and allo‑HSCT groups. Next, the overall survival (OS) and event‑free survival (EFS) were compared between patients with high and low miR‑425 expression in each of the treatment groups. In the chemotherapy group, high miR‑425 expression was favorable for EFS (P=0.001) and OS (P=0.001) in younger patients (<60 years), whereas it had no effect on EFS and OS in older patients (≥60 years). In the allo‑HSCT group, there was no association between miR‑425 expression levels and clinical outcomes. Further analyses suggested that in the low miR‑425 expression group, EFS and OS were longer in patients treated with allo‑HSCT as compared with those treated with chemotherapy (both P<0.001), whereas no significant differences were observed in the high miR‑425 expression group. In conclusion, the current data indicated that miR‑425 is an independent favorable prognostic factor for younger AML patients undergoing chemotherapy, and its use may facilitate clinical decision‑making in selecting treatment for AML patients. Patients with low miR‑425 expression may benefit from allo‑HSCT, whereas allo‑HSCT did not appear to be beneficial in patients with high miR‑425 expression.

View Figures

View References

1	Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 374:2209–2221. 2016. View Article : Google Scholar : PubMed/NCBI
2	Tsai CH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC, Tseng MH, Chiang YC, Kuo YY, Liu MC, et al: Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia. 30:1485–1492. 2016. View Article : Google Scholar : PubMed/NCBI
3	Ustun C and Marcucci G: Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. Curr Opin Hematol. 22:85–91. 2015. View Article : Google Scholar : PubMed/NCBI
4	Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the european leukemianet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
5	Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
6	Brunetti L, Gundry MC and Goodell MA: DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 7:a0303202017. View Article : Google Scholar : PubMed/NCBI
7	Meyer SC and Levine RL: Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 15:e382–e394. 2014. View Article : Google Scholar : PubMed/NCBI
8	Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, et al: Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 128:686–698. 2016. View Article : Google Scholar : PubMed/NCBI
9	Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 366:1079–1089. 2012. View Article : Google Scholar : PubMed/NCBI
10	Marcucci G, Mrozek K, Radmacher MD, Garzon R and Bloomfield CD: The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood. 117:1121–1129. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhou X, Wen W, Shan X, Zhu W, Xu J, Guo R, Cheng W, Wang F, Qi LW, Chen Y, et al: A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. Oncotarget. 8:6513–6525. 2017.PubMed/NCBI
12	Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
13	Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 111:3183–3189. 2008. View Article : Google Scholar : PubMed/NCBI
14	Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, et al: Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol. 28:5257–5264. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sun SM, Rockova V, Bullinger L, Dijkstra MK, Döhner H, Löwenberg B and Jongen-Lavrencic M: The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML. Leukemia. 27:100–106. 2013. View Article : Google Scholar : PubMed/NCBI
16	Zhang Z, Wen M, Guo J, Shi J, Wang Z, Tan B, Zhang G, Zheng X and Zhang A: Clinical value of miR-425-5p detection and its association with cell proliferation and apoptosis of gastric cancer. Pathol Res Pract. 213:929–937. 2017. View Article : Google Scholar : PubMed/NCBI
17	Fang F, Song T, Zhang T, Cui Y, Zhang G and Xiong Q: MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. Oncotarget. 8:31745–31757. 2017.PubMed/NCBI
18	Zhang Y, Hu X, Miao X, Zhu K, Cui S, Meng Q, Sun J and Wang T: MicroRNA-425-5p regulates chemoresistance in colorectal cancer cells via regulation of programmed cell death 10. J Cell Mol Med. 20:360–369. 2016. View Article : Google Scholar : PubMed/NCBI
19	Sun L, Jiang R, Li J, Wang B, Ma C, Lv Y and Mu N: MicoRNA-425-5p is a potential prognostic biomarker for cervical cancer. Ann Clin Biochem. 54:127–133. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yan YF, Gong FM, Wang BS and Zheng W: MiR-425-5p promotes tumor progression via modulation of CYLD in gastric cancer. Eur Rev Med Pharmacol Sci. 21:2130–2136. 2017.PubMed/NCBI
21	Liu P, Hu Y, Ma L, Du M, Xia L and Hu Z: miR-425 inhibits melanoma metastasis through repression of PI3K-Akt pathway by targeting IGF-1. Biomed Pharmacother. 75:51–57. 2015. View Article : Google Scholar : PubMed/NCBI
22	Cancer Genome Atlas Research Network, . Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
23	Conway O'Brien E, Prideaux S and Chevassut T: The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014:1031752014.PubMed/NCBI
24	Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrózek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 30:742–750. 2012. View Article : Google Scholar : PubMed/NCBI
25	Gupta V, Tallman MS and Weisdorf DJ: Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood. 117:2307–2318. 2011. View Article : Google Scholar : PubMed/NCBI
26	Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, et al: Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 126:2062–2069. 2015. View Article : Google Scholar : PubMed/NCBI